A Look At BioMarin Pharmaceutical (BMRN) Valuation After A Year Of Softer Share Price Momentum

BioMarin Pharmaceutical (BMRN) is back on investor watch after recent trading left the shares about 20% lower over the past year, despite annual revenue of US$3.2b and net income of US$348.9m.

See our latest analysis for BioMarin Pharmaceutical.

The recent 1 day share price return of 1.85% decline and 7 day share price return of 5.67% decline sit against a 90 day share price return of 10.93% and a 1 year total shareholder return of 19.73% decline, suggesting short term momentum has softened while the longer term picture remains under pressure.

If you are weighing BioMarin alongside other opportunities in healthcare, this could be a good time to scan for differentiated growth stories in rare disease and treatment platforms using the 33 healthcare AI stocks.

With BioMarin trading well below analyst targets and carrying a low value score of 2 despite US$3.2b in revenue and US$348.9m in net income, are you looking at a mispriced rare disease specialist, or a market that is already discounting future growth?

Most Popular Narrative: 35.2% Undervalued

The most followed narrative pegs BioMarin’s fair value at about $88.65, well above the last close of $57.43. This frames a sizeable valuation gap for investors to assess.

Recent Street research on BioMarin Pharmaceutical reflects a mix of optimism and caution, with analysts updating their views on the company’s execution, growth profile, and valuation assumptions. For you as an investor, the key is understanding where they see potential upside and where they see risks that could justify more conservative fair value estimates.

Read the complete narrative.

Curious what supports that higher fair value? The narrative leans on a specific path for revenue, profitability, and the earnings multiple. The exact mix may surprise you.

Result: Fair Value of $88.65 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story could shift quickly if competition squeezes VOXZOGO and future CNP therapies, or if higher R&D and SG&A spending weighs on margins.

Find out about the key risks to this BioMarin Pharmaceutical narrative.

Another View: Multiples Paint a Tougher Picture

While the popular narrative points to a fair value well above the current $57.43 share price, the market is applying a P/E of 31.7x, compared with 20.6x for the US Biotechs industry and 19.8x for peers. The fair ratio sits at 25.7x, which implies less valuation cushion than the narrative suggests. How comfortable are you paying a premium today for a story that still has execution questions?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:BMRN P/E Ratio as at Mar 2026Next Steps

If this mix of optimism and concern feels familiar, use it as a prompt to look at the data yourself and decide quickly where you stand, then weigh the story against the 2 key rewards and 2 important warning signs.

Ready To Hunt For More Ideas?

If BioMarin has your attention, do not stop here. Broaden your opportunity set by scanning other stocks that match clear, data backed criteria using the Simply Wall Street Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com